Skip to main content

Advertisement

SpringerLink
Log in

Immunotherapy for nonsmall-cell lung cancer

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Abstract

Systemic chemotherapy for nonsmall-cell lung cancer (NSCLC) has reached a plateau in effectiveness for several years and certainly biological therapy (approved antiangiogenic agents and tyrosine kinase inhibitors) has slightly improved survival; however, the mortality of NSCLC is very high and survival of metastatic disease is less than 2 years. Therefore, new approaches are required to improve current outcomes. Active-specific immunotherapy is an area of oncology that is rapidly expanding and delivering promising results such as asymptomatic prostate cancer with the use of sipuleucel-T. In the field of lung cancer, there are multiple vaccines focused on creating specific antitumor activity in NSCLC. Whole-cell vaccines like belagenpumatucel-L and antigen-specific vaccines like L-BLP25, TG4010, EGF vaccine and MAGE-A3 vaccines are undergoing phase III clinical trials after having demonstrated encouraging results in previous phase II trials with minimum toxicity. Hopefully, positive results will be revealed in the next few years, giving our lung cancer patients a new and more personalized therapy with better quality of life. The short review is indented to give an overview of the current data in the main studies of active immunotherapy for NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.

    Article  PubMed  Google Scholar 

  2. Rosell R, Skrzypski M, Jassem E, et al. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS One. 2007;2(11):e1129.

    Article  PubMed  Google Scholar 

  3. Holt GE, Podack ER, Raez LE. Immunotherapy as a strategy for the treatment of nonsmall cell lung cancer. Therapy. 2011;8(1):43–54.

    Article  CAS  PubMed  Google Scholar 

  4. Gross S, Walden P. Immunosuppressive mechanisms in human tumors: Why we still cannot cure cancer? Immunol Lett. 2008;116(1):7–14.

    Article  CAS  PubMed  Google Scholar 

  5. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration resistant prostate cancer. N Engl J Med. 2010;363(5):411–22.

    Article  CAS  PubMed  Google Scholar 

  6. Kong F, Jirtle RL, Huang DH, et al. Plasma transforming growth factor-b1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer. 1999;86(9):1712–9.

    Article  CAS  PubMed  Google Scholar 

  7. Nemunaitis J, Dillman RO, Schwarzenberger PO, et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol. 2006;24(29):4721–30.

    Article  CAS  PubMed  Google Scholar 

  8. Clinicaltrials.gov: Phase III Lucanix vaccine therapy in advanced non-small-cell lung cancer (NSCLC) following front-line chemotherapy (STOP). www.clinicaltrials.gov/ct2/show/NCT00676507. Accessed 1 Feb. 2012.

  9. Sienel W, Varwerk C, Linder A, et al. Melanoma associated antigen (MAGE)-A3 expression in stages I and II non-small cell lung cancer: results of a multi-center study. Eur J Cardiothorac Surg. 2004;25(1):131–4.

    Article  CAS  PubMed  Google Scholar 

  10. Vansteenkiste J, Zielinski M, Linder A, et al. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol. 2007;s25:7554 (Meeting Abstracts).

    Google Scholar 

  11. Clinicaltrials.gov: GSK1572932A antigen-specific cancer immunotherapeutic as adjuvant therapy in patients with non-small-cell lung cancer.http:\\www.clinicaltrials.gov/ct2/show/NCT00480025. Accessed 1 Feb. 2012.

  12. Raina D, Kosugi M, Ahmad R, et al. Dependence on the MUC1-C oncoprotein in non-small-cell lung cancer cells. Mol. Cancer Ther. 2011;10(5):806–16.

    Article  CAS  PubMed  Google Scholar 

  13. Butts C, Murray N, Maksymiuk A, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol. 2005;23(27):6674–81.

    Article  CAS  PubMed  Google Scholar 

  14. Butts C, Maksymiuk A, Goss G, et al. A multi-centre phase IIB randomized controlled study of BLP25 liposome vaccine (L-BLP25 or Stimuvax) for active specific immunotherapy of non-small cell lung cancer (NSCLC): updated survival analysis: B1-01. J Thor Oncol. 2007;2(8):s332–3.

    Article  Google Scholar 

  15. Butts C, Murray RN, Smith CJ, et al. A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-small-cell lung cancer. Clin Lung Cancer. 2010;11(6):391–5.

    Article  CAS  PubMed  Google Scholar 

  16. Clinicaltrials.gov: Cancer vaccine study for unresectable stage III non-small-cell lung cancer.http:\\www.clinicaltrials.gov/ct2/show/NCT00409188. Accessed 1 Feb 2012.

  17. Rochlitz C, Figlin R, Squiban P, et al. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med. 2003;5(8):690–9.

    Article  CAS  PubMed  Google Scholar 

  18. Ramlau R, Quoix E, Rolski J, et al. A phase II study of Tg4010 (Mva-Muc1-IL2) in association with chemotherapy in patients with stage III/IV non-small cell lung cancer. J Thorac Oncol. 2008;3(7):735–44.

    Article  PubMed  Google Scholar 

  19. Acres B, Quoix E, Ramlau R, et al. Biomarkers associated with clinical outcome in advanced non-small cell lung cancer patients treated with TG4010. J Clin Oncol. 2009;s27:3027 (Meeting Abstracts).

    Google Scholar 

  20. Clinicaltrials.gov: Immunotherapy with TG4010 in patients with advanced non-small-cell lung cancerhttp://clinicaltrials.gov/ct2/show/NCT01383148. Accessed 1 Feb 2012.

  21. Rodriguez G, Albisa A, Viña L, et al. Manufacturing process development for an epidermal growth factor-based cancer vaccine. Int Biopharm. 2008;21(10):36–42.

    Google Scholar 

  22. Gonzalez G, Crombet T, Catala M, et al. A novel cancer vaccine composed of human recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann Oncol. 1998;9(4):431–5.

    Article  CAS  PubMed  Google Scholar 

  23. Garcia B, Neninger E, de la Torre A, et al. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clin Cancer Res. 2008;14(3):840–6.

    Article  CAS  PubMed  Google Scholar 

  24. Neninger Vinageras E, de la Torre A, Osorio Rodriguez M, et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol. 2008;26(9):1452–8.

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

Dr. Raez receives research support from MerK Serono and GlaxoSmithKline. Dr. Belalcazar and Dr. Santos do not have a conflict of interest.

Author information

Authors and Affiliations

  1. University of Tennessee Health Science Center, 910 Madison, Suite 1002, 38163, Memphis, TN, USA

    Astrid Belalcazar MD

  2. Memorial Cancer Institute, Memorial Health Care System, Hollywood, FL, USA

    Luis E. Raez MD, FACP, FCCP, MACSG

  3. Herbert Wertheim College of Medicine, Florida International University, 801 N. Flamingo Road suite 11, Pembroke Pines, FL, 33028, USA

    Luis E. Raez MD, FACP, FCCP, MACSG

  4. Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, 1475 NW 12 Avenue # 3510, 33136, Miami, FL, USA

    Edgardo S. Santos MD, FACP

Authors
  1. Astrid Belalcazar MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luis E. Raez MD, FACP, FCCP, MACSG
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Edgardo S. Santos MD, FACP
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luis E. Raez MD, FACP, FCCP, MACSG.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Belalcazar, A., Raez, L. & Santos, E. Immunotherapy for nonsmall-cell lung cancer. memo 5, 90–93 (2012). https://doi.org/10.1007/s12254-012-0019-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-012-0019-y

Keywords

Search

Navigation